Local view for "http://purl.org/linkedpolitics/eu/plenary/2001-10-04-Speech-4-020"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2001-10-04"^^xsd:date2
dcterms:Is Part Of	lp_eu:Poverty reduction (combating the major transmissible diseases)2
dcterms:Language	"nl"^^xsd:language2
lpv:document identification number	"en.20011004.2.4-020"2
lpv:hasSubsequent	lp_eu:2001-10-04-Speech-4-0212
lpv:speaker	lp:Dorette Corbey2
lpv:spokenAs	substitute; Committee on Industry, External Trade, Research and Energy (1999-07-22--2002-01-14)3 unknown; Partij van de Arbeid (1999-07-20--2004-07-19)3 substitute; Delegation to the EU-Turkey Joint Parliamentary Committee (1999-10-08--2002-01-14)3 substitute; Temporary committee on human genetics and other new technologies in modern medicine (2000-12-13--2001-11-29)3 member; PES (1999-07-20--2004-07-19)3 member; Committee on the Environment, Public Health and Consumer Policy (1999-07-21--2002-01-14)3
lpv:translated text	"Mr President, five million people die each year of AIDS, malaria and tuberculosis in developing countries. One of the reasons for this is that medicines are for the most part too expensive for the people of those countries. And medicines are often unavailable altogether. Of the more than 1 450 new medicines which have come onto the market in the last twenty years, only thirteen are intended for tropical diseases. There is a severe lack of effective medicines in developing countries. They are either non-existent or too expensive. It would appear that investment in treatment of tropical diseases is not profitable enough for pharmaceutical companies. A more tragic example of the failure of the market is hard to imagine. These sad facts give the Committee on Industry, External Trade, Research and Energy cause to propose drastic measures. Firstly, we propose a system of differentiated pricing. Medications should be made available free of charge or at affordable prices. For this, it will be necessary to prevent re-importation, and the industry’s cooperation will be essential in this. Secondly, there is the matter of patents. Rapporteur Khanbhai mentioned the great importance of these. Nevertheless, the Committee on Industry, External Trade, Research and Energy proposes to shorten the period of patent protection for essential medicines in developing countries. This is important, since in 2005 and 2006, the TRIPS Agreement is to be implemented in developing countries. By then, there will be major problems in combating AIDS and also tuberculosis. If the system of differentiated pricing works, this measure will not be necessary. But should it not succeed completely, it would be an important weapon in the battle against disease in developing countries. A third point which is also of extreme importance to the Committee on Industry, External Trade, Research and Energy is an extensive European research programme. This is necessary to tailor pharmaceutical research more to existing needs. Therefore more research into, and investment in, treatment of tropical diseases, but also investment in remedies which can be used in developing countries. Remedies which, for example, do not require refrigerated storage. Cooperation with the developing countries is essential, and a substantial increase in the budget to go along with this. I thank the rapporteur for his cooperation and for his willingness to listen to other committees."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph